The influence of previous stereotactic thalamotomy on l-dopa therapy in Parkinson's disease
Selby, G.
Proceedings of the Australian Association of Neurologists 13: 55-60
1976
ISSN/ISBN: 0084-7224 PMID: 800866 Document Number: 101871
Document emailed within 1 workday
Related Documents
Kostiuk, K.; Lomadze, V.; Vasyliv, N. 2017: Stereotactic Thalamotomy and Contralateral Subthalamotomy in Treatment of Parkinson's Disease Georgian Medical News 272: 12-17Lee, S.T.; Lu, C.S. 1996: Ventrolateral thalamotomy for dyskinesia following levodopa therapy of Parkinson's disease Journal of the Formosan Medical Association 95(12): 943-945
Routh, J.I.; Bannow, R.E.; Fincham, R.W.; Stoll, J.L. 1971: Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy Clinical Chemistry 17(9): 867-871
Muenter, M.D.; Tyce, G.M. 1971: L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects Mayo Clinic Proceedings 46(4): 231-239
Indo, T.; Takahashi, A. 1987: Should L-dopa therapy for Parkinson's disease be started early or late? Clinical course of the major tetrad in 122 Parkinsonian patients treated with L-dopa over 14 years Rinsho Shinkeigaku 27(11): 1419-1422
Muenter, M.D.; Sharpless, N.S.; Tyce, G.M. 1972: Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease Mayo Clinic Proceedings 47(6): 389-395
Petit, H. 1984: Early or late dopa therapy in Parkinson's disease Presse Medicale 13(36): 2213
Broussolle, E. 2000: Dopa-therapy in the treatment of early stage Parkinson's disease Revue Neurologique (Paris) 156(2 Part 2): 91-97
Gauthier, G.; de Ajuriaguerra, J.; Geissbuhler, F.; Simona, B.; Constantinidis, J.; Yanniotis, G.; Krassoievitch, M.; Eisenring, J.J.; Tissot, R. 1971: Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa? La Presse Medicale 79(3): 91-92
Lipman, I.J.; Papadopoulos, N.M. 1973: Cerebrospinal fluid N-acetyl neuraminic acid in Parkinson's disease, before and after L-dopa therapy Diseases of the Nervous System 34(1): 59-62
Fuchs, G. 1997: Parkinson disease--problems in long-term treatment. Dopamine agonists optimize L-dopa therapy Fortschritte der Medizin 115(5): 43-45
Iacono, R.P.; Osborne, D.R.; Nashold, B.S. 1984: CT analysis of stereotactic thalamotomy Advances in Neurology 40: 453-458
Christiani, K.; Möller, W.D. 1973: Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor Münchener Medizinische Wochenschrift 115(16): 711-713
Sławek, Jłav.; Friedman, A.; Bogucki, A.; Opala, G. 2007: Stereotactic pallidotomy and thalamotomy in the treatment of primary dystonia Neurologia i Neurochirurgia Polska 41(2): 188-9; Author Reply 190-1
Balás, I.; Llumiguano, C.; Horvath, Z.; Kovér, F.; Dóczi, T.P. 2000: MRi guided stereotactic thalamotomy for the treatment of the neurogenic pain Revista de Neurologia 31(6): 531-533
Dalle Ore, G.; Bricolo, A.; Robotti, E.; Bazzan, A.; Mazza, C. 1970: The treatment of Parkinson's disease with L-dopa Il Policlinico. Sezione Pratica 77(16): 509-524
Völler, G. 1970: L-dopa in the treatment of Parkinson's disease Die Medizinische Welt 27: 1267-1268
Lees, A.J. 1986: L-dopa treatment and Parkinson's disease Quarterly Journal of Medicine 59(230): 535-547
Gildenberg, P.L. 1984: The present role of stereotactic surgery in the management of Parkinson's disease Advances in Neurology 40: 447-452
Ginath, Y.; Lavy, S.; Abramsky, O.; Carmon, A. 1971: Mental complications of L-dopa therapy in Parkinson's patients Israel Annals of Psychiatry and Related Disciplines 9(3): 252-264